3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Myeloid
1
CNS
1
Conditions
Lymphoma
138
Lymphoma, Non-Hodgkin
84
Lymphoma, Large B-Cell, Diffuse
83
Small Cell Lung Carcinoma
78
Hodgkin Disease
61
Precursor Cell Lymphoblastic Leukemia-Lymphoma
59
Leukemia
57
Burkitt Lymphoma
56
Lung Neoplasms
49
Lymphoma, Follicular
47
Lymphoma, Mantle-Cell
44
Leukemia, Myeloid, Acute
41
Lymphoma, Large-Cell, Immunoblastic
40
Multiple Myeloma
33
Leukemia, Lymphocytic, Chronic, B-Cell
33
Carcinoma, Non-Small-Cell Lung
30
Recurrence
26
Neuroblastoma
25
Lymphoma, B-Cell, Marginal Zone
25
Central Nervous System Neoplasms
24
Ovarian Neoplasms
18
Sarcoma
17
Brain Neoplasms
17
Dendritic Cell Sarcoma, Interdigitating
16
Congenital Abnormalities
16
Lymphoma, Large-Cell, Anaplastic
15
Breast Neoplasms
15
Testicular Neoplasms
14
Neoplasms, Plasma Cell
14
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
olaparib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
Vemurafenib
2
LY3023414
2
Cyclophosphamide
2
thymoglobulin
1
fludarabine
1
etoposide phosphate
1
cobimetinib
1
Whole-Body Irradiation
1
Tacrolimus
1
Sirolimus
1
Rituximab
1
Pharmacogenomic Variants
1
Mycophenolic Acid
1
Melphalan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Histiocytosis, Langerhans-Cell
×
Etoposide
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled